INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics, a private hi-tech medical technology company focused on the development...
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of...
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif.,...
Dr Hoekema brings over four decades of successful biotech and life science leadershipDr Cora Griffin appointed to head up business...
-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI...
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary...
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based...
HITRUST certification affirms TeleSpecialists' commitment to leading security practices to protect sensitive information FORT MYERS, Fla., Sept. 25, 2024 /PRNewswire/...
Chief Strategy Officer Dr. John Showalter will also explain during FMX Med Talk why early detection of cognitive impairment by...
Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting...
MILAN, Sept. 25, 2024 /PRNewswire/ -- The new edition of "Preserving the Brain," part of Fondazione Prada's "Human Brains" project...
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within...
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurologySOUTH SAN FRANCISCO, Calif.,...
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase...
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disordersNEW YORK,...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including...
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it...
Verified Market Research® proudly announces the release of its latest comprehensive market research report, "Physiotherapy Equipment Market," offering critical insights...
Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September...
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated...